Capricor Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27, Implies 228% Upside

What happened

Capricor Therapeutics’ average 12-month share-price target rose from $23.67 to $27, based on estimates from five analysts. The article says that, using the Nov. 3 closing price, the new target implies about 228% potential upside; the overall rating from 10 analysts remains Buy.

Confirmed

Global impact / market context

A higher target signals that the analysts providing estimates now see more possible share-price value, which could influence investor expectations and positioning in Capricor. However, it is a forecast, not a company result or guarantee, and the wide range shows substantial disagreement.

Analyst inference

The target estimates range from $7 to $54 per share, while the overall rating remains Buy, comprising four Buys, six Holds and no Sells. The increase is based on five analysts’ estimates, fewer than the 10 analysts contributing to the overall rating.

Confirmed

What to watch

1. Check whether later analyst updates keep the average target near $27 or change it; the article gives no explanation for why the five analysts raised their estimates. Analyst inference
2. Compare subsequent company results and disclosures with the expectations embedded in analyst forecasts, since the article provides no operating results or evidence that the implied upside will be achieved. Analyst inference
3. Note that the five target estimates span $7 to $54 per share, a wide difference that signals analysts do not share one precise view of value. Confirmed

Evidence

• Original source link unavailable